Anticoagulation Management

Introduction to Anticoagulant Conversion

When converting a patient from apixaban to enoxaparin, discontinue apixaban and begin enoxaparin at the time the next dose of apixaban would have been taken, to avoid increased bleeding risk 1
The American Heart Association recommends avoiding simultaneous administration of apixaban and enoxaparin, as this significantly increases bleeding risk, as stated in Circulation 1

For patients <75 years of age, the recommended dose of enoxaparin is 1 mg/kg subcutaneously every 12 hours, according to the European Heart Journal 2
For patients ≥75 years of age, the recommended dose of enoxaparin is 0.75 mg/kg subcutaneously every 12 hours without an initial IV bolus, as suggested by the European Heart Journal 2
For patients with a body mass index (BMI) ≥40 kg/m², a reduced dose of 0.8 mg/kg subcutaneously every 12 hours is recommended to achieve adequate anti-Xa levels, as supported by the NCCN guidelines 3
For patients with BMI <40 kg/m², a therapeutic dose of enoxaparin of 1 mg/kg subcutaneously every 12 hours is recommended by the American College of Cardiology and the National Comprehensive Cancer Network, with an alternative regimen of 1.5 mg/kg subcutaneously once daily being less preferred, especially in cancer patients 4, 3, 5
For patients with severe renal insufficiency (CrCl <30 mL/min), a dose adjustment to 1 mg/kg once daily is recommended, along with monitoring of anti-Xa levels, as suggested by the NCCN and the European Heart Journal 3, 6, 5

Patients initially treated with enoxaparin should not be switched to unfractionated heparin and vice versa, due to increased risk of bleeding, as reported in Circulation 7
Elderly patients may benefit from reduced dosing (0.75 mg/kg every 12 hours) and should be monitored closely for bleeding complications, according to the European Heart Journal 2
Complete blood count monitoring is recommended every 2-3 days during the first 2 weeks, then every 2 weeks or as clinically necessary, with platelet counts being monitored due to the risk of heparin-induced thrombocytopenia, as suggested by the NCCN and the European Heart Journal 3, 5, 8
Anti-Xa level monitoring is not routine but should be considered in patients with severe renal insufficiency or pregnancy 5

The standard duration of anticoagulation therapy should be at least 3 months for provoked PE, and extended or indefinite therapy is recommended for unprovoked PE or recurrent VTE, according to the European Heart Journal and the National Comprehensive Cancer Network 9, 3, 8
Enoxaparin has been shown to be as effective and safe as unfractionated heparin in preventing recurrences of symptomatic venous thromboembolic events, with a recurrence rate of 2.9% with enoxaparin twice daily, 4.4% with enoxaparin once daily, and 4.1% with unfractionated heparin, and similar rates of major bleeding: 1.3%, 1.7%, and 2.1%, respectively 3
A minimum of 5 days of parenteral anticoagulation is recommended, followed by oral anticoagulation as appropriate, typically for at least 3-6 months, according to the NCCN 8
The American College of Cardiology's 2021 expert consensus pathway and the 2024 National Comprehensive Cancer Network guidelines support the recommendation for 1 mg/kg twice daily dosing with high-quality evidence 4, 3